Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results

Oncologist. 2023 May 8;28(5):e309-e312. doi: 10.1093/oncolo/oyad008.


Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling through inhibition of CYP17, showed promising efficacy and a manageable safety profile in this patient population.

Keywords: PARP inhibitor; abiraterone acetate; castration-resistant prostate cancer; homologous recombination repair; niraparib.

Publication types

  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abiraterone Acetate* / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Humans
  • Male
  • Prednisone / adverse effects
  • Prostatic Neoplasms, Castration-Resistant* / drug therapy
  • Prostatic Neoplasms, Castration-Resistant* / pathology
  • Treatment Outcome


  • Abiraterone Acetate
  • Prednisone
  • niraparib